Additionally, BAs have emerged as vital signaling molecules that regulate glucose and lipid metabolism by interacting with Farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5), highlighting their potential as novel therapeutic targets for GDM management. This evidence concerns the gene NR1H4 and gestational diabetes.